INDUCED STEVENS-JOHNSON SYNDROME IN A HUMAN IMMUNODEFICIENCY VIRUS PATIENT: A CASE REPORT

ABSTRACTStevens-Johnson syndrome (SJS) is an acute life-threatening condition. In 95% of case reports, drugs were found to be an important cause for thedevelopment of SJS. About 100 drugs have been identified to causes of SJS. Very few reports were published on diclofenac-induced SJS. The incidencerate of SJS is approximately 1-2/1000 individuals with human immunodeficiency virus. In this case report, we present a 58-year-old female developedSJS after taking of diclofenac tablets.Keywords: Stevens-Johnson syndrome, Diclofenac, Human immunodeficiency virus patients

Impact of Pharmacist–Psychiatrist Collaborative Patient Education on Medication Adherence and Quality of Life (QOL) of Bipolar Affective Disorder (BPAD) Patients

Background: Bipolar Affective Disorder (BPAD) is one of the leading causes of disability globally. Medication non-adherence and low quality of life (QOL) are the major challenges associated with the treatment of BPAD patients.Objective: Aim of this study was to assess the impact of pharmacist–psychiatrist collaborative patient education on medication adherence and QOL of BPAD patients.Methodology: A prospective randomized control study was conducted in the psychiatry outpatient department in a tertiary care setting. The eligible patients were enrolled and randomized into test (collaborative care) and control (usual care) groups. Patient education was provided by pharmacists to the test group patients, along with the usual care provided to all the patients. Patients were followed for three follow-ups of nearly 1 month intervals. Medication adherence and QOL were assessed by Medication Adherence Rating Scale and WHOQOL-BREF questionnaire, respectively. T-test was used and P-values < 0.05 were considered statistically significant.Results: Out of 75 patients enrolled, 73 patients were followed for all the three follow-ups and completed the study. Thirty-eight patients belonged to test and 35 were in control group. The mean age of patients was 34.21 ± 10.91 years. Forty-eight (65.75%) patients belonged to age group of 18–39 years. There were 41 males (56.16%) and 32 female patients (43.83%) in the study. Mean improvement in medication adherence and QOL of the test and control groups were found to be 2.06 ± 0.15 (<0.001) and 13.8 ± 10.5 (<0.05), respectively.Conclusion: This study concluded that pharmacist–psychiatrist collaborative patient education can significantly improve the medication adherence and QOL of the BPAD patients. Statistically significant results indicating improved patient care and outcomes were possible when pharmacists worked as a team with psychiatrists

Impact of pharmacist-led collaborative patient education on medication adherence and quality of life of schizophrenia patients in a tertiary care setting

Schizophrenia is a chronic mental-disorder and one of the top 10 causes of disability globally. Nearly 4.3 million people suffer from schizophrenia in India but very few visit a hospital for diagnosis or treatment. Of those patients who receive treatment, medication non-adherence and decreased quality of life (QOL) are the major problems. The objective of study was to assess the impact of pharmacist-led collaborative patient education on medication adherence and QOL in schizophrenia patients in a psychiatry out-patient setting of a tertiary-care setting. Patients were randomized into two groups. Interventional patients received medication review, followed by patient education session using Patient-Information Leaflets (PILs) developed for the study. Control patients received usual-care. Patients data were collected at the beginning of the study and after each follow-up of one-month interval, till 3rd follow-up. Medication adherence and QOL were assessed using Medication Adherence Rating Scale and WHOQOL-BREF questionnaire respectively. Twenty-three patients completed the study, 13 were in the intervention and 10 in the control group. Majority of the study subjects were of age group 18â39 years (69.56%) and female (65.21%). Medication adherence mean improvement was 0.7 ± 0.67 and 1.75 ± 0.2 in control and intervention groups respectively. Similarly, mean QOL improvement was 16.12 ± 1.98 and 24.17 ± 0.3 in control and intervention groups respectively. Statistically significant improvement in the mean medication adherence and QOL was observed in the intervention group. Results showed that pharmacist-psychiatrist collaborative care can significantly improve patientsâ medication adherence and QOL. Keywords: Schizophrenia, Collaborative care, Medication adherence, Quality of life, Pharmacis